Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC
Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC
Adjuvant temozolomide improves survival in IDH-mutant anaplastic glioma
Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours
Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers
ELCC 2025: Latest in EGFR positive NSCLC
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC
Urine test could reduce post-op scans for kidney cancer by half
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC